Please login to the form below

Not currently logged in
Email:
Password:

Once daily anti-epileptic drug launches

Eisai announced the launch of Zebinix (eslicarbazepine acetate) in the UK on
November 9
A novel, once daily anti-epileptic, Zebinix (eslicarbazepine acetate), has been launched in the UK  as adjunctive therapy in adults with partial-onset seizures, with or without secondary generalisation.
 
Developed from the current 'gold standard' treatment carbamazepine (launched in 1965), Zebinix (eslicarbazepine acetate) offers patients improved seizure control with a favourable safety profile. Eslicarbazepine acetate is a voltage gated sodium channel blocker that has a higher affinity for the inactivated state of the channel compared with the resting state. This suggests an enhanced inhibitory selectivity for rapidly firing neurons over those displaying normal activity. Eslicarbazepine acetate has been developed to avoid formation of the epoxide metabolite, which has been associated with neurological side effects.

Patients using Zebinix (eslicarbazepine acetate) reported improvements in health-related quality of life measures such as 'seizure worry' and 'cognitive function', as well as improvement in the MADRS (Montgomery-Asberg Depression Rating Scale) depressive symptoms' scale. Depression is often reported by patients with poorly controlled epilepsy.

“Continued seizures bring significant risk of poor quality of life, reduced employment and the development of mental illness such as depression or anxiety. The launch of eslicarbazepine acetate should offer a new choice for patients and clinicians in reducing the burden of epilepsy," said Mike Kerr, professor of learning disabilities at Cardiff University, who has a special interest in the treatment and psychological impact of epilepsy.
 
The efficacy, safety and tolerability of eslicarbazepine acetate (ESL) has been demonstrated in three phase III double-blind, randomised placebo-controlled trials in 1,049 adult patients with partial onset seizures. Eslicarbazepine acetate demonstrated significant and sustained reductions in seizure frequency and significant increases in responder rates. These studies also demonstrated that patients continued to take eslicarbazepine acetate, with retention rates ranging from 68-79 per cent at one year. The median daily dose throughout this one-year treatment was 800mg. Treatment-emergent adverse events, including dizziness, headache and somnolence, affected less than 10 per cent of patients in the pivotal studies.
 
Eslicarbazepine acetate is also novel in that it can be given as a true one tablet once-a-day regimen at its median daily dose as defined in clinical trials as 800mg.

Epilepsy affects approximately 1 in 100 people – and the successful treatment of partial-onset seizures (the most common type of epilepsy) remains a challenge. Up to 40 per cent of patients with partial seizures do not achieve seizure control with current anti-epileptics.

9th November 2009

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Solaris Health

The beauty of detail: an effective, compelling medical communications campaign requires each component to be carefully planned, expertly crafted and...

Latest intelligence

Is the pharma business model ready for precision medicine?
Precision medicine promises to revolutionise patient outcomes and reduce costs for industry but is pharma ready for it? Blue Latitude Health co-founder Head of Strategy Fred Bassett explores the challenges...
ABPI2018
The NHS and ABPI at 70: inching closer to the triple win
The NHS and UK pharma’s ABPI both turn 70 this year. After years of transactional relationships, there’s a will to work more closely - but friction on prices and value...
What pharma marketers can learn from behavioural science
Pharma behavioural science and traditional emotional marketing create a powerful mix of techniques that have impact on real lives....

Infographics